Merck to Acquire Idenix

Dateline City: WHITEHOUSE STATION, N.J. & CAMBRIDGE, Mass. Acquisition Expands Portfolio of Promising Investigational Therapies for Hepatitis C WHITEHOUSE STATION, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX), today announced that the companies have entered into a definitive agreement under which Merck will acquire Idenix for $24.50 per share in cash. The transaction, which values the purchase of Idenix at approximately $3.85 billion, has been approved by the boards of directors of both companies. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Steve Cragle, 908-423-3461orInvestors:Joe Romanelli, 908-423-5185Justin Holko, 908-423-5088orIdenixMedia/Investors:Teri Dahlman, 617-995-9807 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Source: Merck.com - Corporate News - Category: Pharmaceuticals Tags: Corporate News Latest News Source Type: news